Zenas BioPharma, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company focused on the development and commercialization of immunology-based therapies for patients with autoimmune diseases. The company advances a pipeline featuring its lead candidate obexelimab, a bifunctional monoclonal antibody that binds CD19 and FcγRIIb to suppress B cell activity without depletion in indications including immunoglobulin G4-related disease (IgG4-RD) in the ongoing Phase 3 INDIGO trial, relapsing multiple sclerosis (RMS) with Phase 2 MoonStone data expected in Q1 2026, and systemic lupus erythematosus (SLE) in the Phase 2 SunStone trial; orelabrutinib, a CNS-penetrant oral BTK inhibitor licensed globally ex-oncology from InnoCare Pharma in October 2025 for primary progressive multiple sclerosis (PPMS) in a Phase 3 trial and secondary progressive MS (SPMS) with initiation planned for Q1 2026; and earlier programs such as ZB002 (anti-TNFα monoclonal antibody), ZB004 (CTLA-4-Ig fusion protein), ZB001 (anti-IGF-1R monoclonal antibody, licensed to Zai Lab in Greater China), ZB021, and ZB022. Founded in 2020 and headquartered in Waltham, Massachusetts, Zenas BioPharma conducts global clinical trials across approximately 20 countries and targets unmet needs in immune-mediated inflammatory diseases for patients worldwide. Recent developments include a transformative October 2025 license agreement with InnoCare Pharma granting global rights to orelabrutinib backed by a $120 million private placement funding operations into Q4 2026, a September 2025 funding deal with Royalty Pharma for up to $300 million in obexelimab royalties to support late-stage development and commercialization, completion of enrollment in the IgG4-RD Phase 3 trial with topline data anticipated by year-end 2025, and an expanded Series C financing of $458 million in 2024 to fuel growth.
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma (NASDAQ:ZBIO) Shares Up 7.6% on Insider Buying Activity
Zenas BioPharma (NASDAQ:ZBIO) versus Twist Bioscience (NASDAQ:TWST) Critical Analysis
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of “Hold” from Analysts
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)